Etoposide

目录号:S1225 别名: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。

规格 价格 库存 购买数量  
RMB 749.41 现货
RMB 575.72 现货
RMB 2290.17 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献17篇:

客户使用该产品的8个实验数据:

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    a Immunofluorescence of HA–cGAS in transfected HCA2-TERT cells exposed to etoposide (100 μg/ml) for 4 h. b, Immunoblot of endogenous cGAS in the cytoplasmic and nuclear fractions of HCA2-TERT cells treated with etoposide for the indicated times

    Nature, 2018, 563(7729):131-136. Etoposide purchased from Selleck.

  • j, Immunoblot of cell lysates of PC-9 cells that stably express HA–cGAS, transfected with either shCtrl or shBLK after etoposide (100 μg ml−1) treatment for 4 h.

    Nature, 2018, 563(7729):131-136. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

产品安全说明书

Topoisomerase抑制剂选择性比较

生物活性

产品描述 Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。
靶点
Topo II [2]
(Cell-free assay)
体外研究

Etoposide通过与Topoisomerase II 和 DNA形成复合物而抑制DNA合成,诱导双链DNA断裂,且阻碍通过 Topoisomerase II结合修复。DNA持续断裂阻碍进入细胞有丝分裂期,进而导致细胞死亡。Etoposide主要作用于细胞周期的G2期和S期。[1] Etoposide 抑制鼠类血管肉瘤细胞系 (ISOS-1) 生长,IC50 为0.25 μg/mL。Etoposide 抑制人类白血病成淋巴细胞系CCRF-CEM的四倍体克隆,IC50为0.6 μM。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NFr3cGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMUNihKnDueLCiUCuNFEh|ryP NWPNc4tKOjV7NkCyPFI>
KellyCis83 M{jBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[wZpM5UUN3ME2wMlE36oDLwsJihKkxNjB{IN88US=> MlW4NlU6PjB{OEK=
SK-N-AS MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESzZm1KSzVyPUCuNlTjiIoEsfMAjVAvODNizszN Ml7xNlU6PjB{OEK=
SK-N-ASCis24 MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwNUhihKnDueLCiUCuNVEh|ryP MmLlNlU6PjB{OEK=
U87 NFfoemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETKPY8xNTVyIN88US=> M2GxdlQ5KGh? MWXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KHOrbHnibY5qdg>? NYTC[4xzOjV5NUCyO|M>
HCT116 MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLBVFMxNjVvMj61JO69VQ>? MX20POKhcMLi NECwPYlKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= NYTUdVNNOjV5NE[3OlM>
HT-29 NVvDUJdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPUNE42NTJwNTFOwG0> MljHOFjDqGkEoB?= M2XBTmlEPTB;Nz6yxsDDucLiMT6wOOKh|ryP NFPTPJQzPTd2Nke2Ny=>
Caco2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe0N45xOC53LUKuOUDPxE1? M3rZXlQ5yqCqwrC= NIf3fXFKSzVyPUeuNlbDqMLzwrCxMlY5yqEQvF2= MXSyOVc1Pjd4Mx?=
COLO 205 M2PDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXa[o81OC53LUKuOUDPxE1? MmPyOFjDqGkEoB?= MnLhTWM2OD1zLk[xxsDDucLiMD6wNuKh|ryP M3zJTFI2PzR4N{[z
SW480 M1fRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nIZ|AvPS1{LkWg{txO NEGwcWM1QMLiaNMg NX3PV25yUUN3ME20MlkzyqEEsdMgNE4{O8LizszN NW\PZ2tlOjV5NE[3OlM>
HEK293T Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoWzNU02KM7:TR?= M4m1U|Q5yqCqwrC= NWH4VpR{UUN3ME2yMlQzyqEEsdMgNE4xPcLizszN MXqyOVc1Pjd4Mx?=
Hep3B  MYTGeY5kfGmxbjDBd5NigQ>? MX[xNEDPxE1? NWCzOW9tPDkEoHlCpC=> MWXy[YR2[2W|IITo[UBmdmijbnPpcoch\W[oZXP0JI9nKEKPUD22 MnzZNlU3OzN3NkS=
Hep3B  MWLGeY5kfGmxbjDBd5NigQ>? M{\wS|AvOS1zMDFOwG0> MkDiNlQhcA>? Mlfnd5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBp\XClaXTpckBuWk6D MXmyOVY{OzV4NB?=
HEK293 MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rHfWlEPTB;Nz6xOOKhyrIEoECuN|bDqM7:TR?= NFrnZ2czPTZyM{GyNi=>
DU145 M1z0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\yUIJKSzVyPUKuNljDqMLzwrCwMlA1yqEQvF2= NYHtNIloOjV4MEOxNlI>
HCT15 Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwOEJCpOKyyqByLkCxxsDPxE1? NF7FXmMzPTZyM{GyNi=>
T47D MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPRVpZKSzVyPUOuNVjDqMLzwrCwMlEyyqEQvF2= NWPQbpU3OjV4MEOxNlI>
SMMC-7721 M3fzVGZ2dmO2aX;uJGF{e2G7 MV:0NEDPxE1? M{PJcVQ5KGh? M3njbGROW09? Moi1bY5lfWOnczFOt2gzSVhiZn;jbUBnd3KvYYTpc44> M2PpbFI2PTR2M{[x
MDA-MB-231 NW\nNpp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M321UlczyqCq NWDhPIRiUUN3ME2yNU4zyqEEsdMgOE4zyqEQvF2= NF\JWXMzPTR6NkKxPS=>
MCF-7 NVW1U5gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWe3NuKhcA>? MULJR|UxRTFyLkpCpOKyyqB{LkJCpO69VQ>? MWmyOVQ5PjJzOR?=
Jurkat NVj5WVFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUiwU21FPzMEoHi= M{TibGlEPTB;MT6yxsDDucLiMT61xsDPxE1? NGL6XoEzPTR6NkKxPS=>
HeLa M{Dtc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnBSoZ2PzMEoHi= NF;RV2hKSzVyPUOuPeKhyrIEoEKuN:Kh|ryP NHT2e|gzPTR6NkKxPS=>
MCF7  MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\xN|UuOTByIN88US=> Mn\aO{Bl MXPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NEjvPXgzPTR5Mk[xPS=>
K562 M4PFNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DQclczyqCq NET4OpJKSzVyPUCuNlnDqM7:TR?= M13zW|I2Ojh{NkWz
K/VP.5 M3nqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXFbZU4OsLiaB?= NVjBSXRlUUN3ME20MlnDqM7:TR?= MmnCNlUzQDJ4NUO=
SH-EP  M{KwW2Z2dmO2aX;uJGF{e2G7 NXzYPGFIOjEEoN88[{9udA>? NFXJeWczPMLiaB?= M3\LfYlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBmdmSxZ3Xuc5V{KESHUGC= MV6yOVI3OTl6MR?=
SCC25 NX7OSHVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HDWVI1yqCq NGPLdWZKSzVyPUSzMlPDqMLzwrCxMlEzyqEQvF2= Mk\6NlUzOjB5Mkm=
CAL27 NFnuUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYGyOOKhcA>? NVXNfHdSUUN3ME21Nk4yyqEEsdMgNU4xQcLizszN Mn7KNlUzOjB5Mkm=
FaDu MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnGZZpNOjUEoHi= MY\JR|UxRTJ3Lki5xsDDucLiMT6xN:Kh|ryP NFfwTWQzPTJ{MEeyPS=>
SCC25 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHSOFjDqGh? M4HyUWlEPTB;MkCuPFbDqMLzwrCxMlA4yqEQvF2= MlLVNlUzOjB5Mkm=
CAL27 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYWzbHlbPDkEoHi= NXfkZ5NoUUN3ME2xPE4zPMLiwsJCpFEvOTYEoN88US=> MmC5NlUzOjB5Mkm=
FaDu NUn1W|lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfaR5o1QMLiaB?= M3riZWlEPTB;Nj60N:KhyrIEoEGuNVPDqM7:TR?= MYWyOVIzODd{OR?=
SCC25 NVvVPZROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnIO|LDqGh? MVzJR|UxRThwNEJCpOKyyqBzLkGxxsDPxE1? NWXnXllrOjV{MkC3Nlk>
CAL27 NH\uZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDoO|LDqGh? NYnoTpkzUUN3ME20MlI4yqEEsdMgNU4yPMLizszN NUm4UGI3OjV{MkC3Nlk>
FaDu MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX6WFA4OsLiaB?= MWHJR|UxRTVwMENCpOKyyqBzLkG1xsDPxE1? NHTZfVgzPTJ{MEeyPS=>
MCF-7 MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjQPFQ1QMLiaNMg NHHyUW9FVVOR M1;PT2lEPTB;Nz6yxsDDucLiMD64xsDPxE1? NYq5W4E6OjV{MU[zO|g>
T-47D Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUi0POKhcMLi M1rSeWROW09? NFrNTGxKSzVyPUeuO:KhyrIEoECuO:Kh|ryP M1jte|I2OjF4M{e4
MDA-MB-231 NHLadWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP1OFjDqGkEoB?= M1fQ[2ROW09? NUHh[Y5pUUN3ME2xNk45yqEEsdMgNU4xyqEQvF2= NEDkWG4zPTJzNkO3PC=>
DU145 M1rIfmFxd3C2b4Ppd{BCe3OjeR?= NXuxfIpjOTBvMUCwJO69VQ>? MmmzPEBp NV3KTYhsTE2VTx?= M1fxZYlv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= NXf2TFFyOjVzNEm2PFE>
DU145 stem-like NVvJVWZCSXCxcITvd4l{KEG|c3H5 MoryNVAuOTByIN88US=> NIjWNGo5KGh? NGXSPYJFVVOR NVS4N|J4cW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1ji[lI2OTR7Nkix
DU145 NELqUoVHfW6ldHnvckBCe3OjeR?= NVjw[Y5POTBvMUCwJO69VQ>? MXmyJIg> NH3HXWRFVVOR MorVbY5kemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGGwZDDk[YNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYHvNXI6OjVzNEm2PFE>
DU145 stem-like MmnqSpVv[3Srb36gRZN{[Xl? MXexNE0yODBizszN NVzjbJZvOiCq NI\OSHhFVVOR MYrpcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MUGyOVE1QTZ6MR?=
UW228-3 NGjTS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf5UW91OC5yMT2zNFAh|ryP NU\NXoxrPDhiaB?= MVHEUXNQ MojsTWM2OD1yLkm5xsDPxE1? M1TyWVI2OTF7MUi1
NSCs NGDhe|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Hwe|AvODFvM{CwJO69VQ>? MYC0PEBp NX3ZeIE4TE2VTx?= NITHN|RKSzVyPUCuN{0{yqEQvF2= MVqyOVEyQTF6NR?=
MKL-1  NVvWb5g4TnWwY4Tpc44hSXO|YYm= M3uwb|ExNTFyMECgcm0> M1HTR|Qh\A>? M4Cyc4lv\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDNTGMuUSCneIDy[ZN{cW:w MVGyOVEyPjd3NB?=
MCF7 EV MYfGeY5kfGmxbjDBd5NigQ>? MoDYNVAuOTByIN88US=> NWLZN4x1OuLCiXi= NXu2RnlmcW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? NFSzXmkzPTB6OEKwNy=>
MCF 7BMI1 NVLKV5U1TnWwY4Tpc44hSXO|YYm= M2O4Z|ExNTFyMDFOwG0> NWjFN4JSOuLCiXi= MVHpcoR2[2W|IIDyc4R2[3Srb36gc4bDqM7|SELBXC=> M2\pc|I2ODh6MkCz
MCF7 EV MmPDSpVv[3Srb36gRZN{[Xl? MlLQNVAuOTByIN88US=> MlzRNwKBkWh? M1[xeWVVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> NXroT4h4OjVyOEiyNFM>
MCF7 BMI1 MkfUSpVv[3Srb36gRZN{[Xl? MmTmNVAuOTByIN88US=> MnrxNwKBkWh? NXHKR29STVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v MWeyOVA5QDJyMx?=
HepG2 Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DKVGROW00EoB?= MlPwTWM2OD1|MD6xOuKhyrIEoECuOVDDqM7:TR?= Mn:2NlUxPzh|MUG=
MOLT-3 M2Tle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofTSG1UV8Li M{HjdGlEPTB;MD6wOVHDqMLzwrCwMlAxOsLizszN NYfScotiOjVyN{izNVE>
HT1080 NWX4XFljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjGc28yNTFyMDFOwG0> MlS2OE8zPC92ODDo Mo\jSG1UV8Li MUHpcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? NFzBe3YzPTB5OEC2OC=>
HT1080 M2nUU2Z2dmO2aX;uJGF{e2G7 NGTF[2wxNjByMEGtNVAxKM7:TR?= MVKxMVI1KGh? NFz0fHhFVVORwrC= NHTIUI5qdmS3Y3XzJJAueDV|KIPldlE2MSCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= MVeyOVA4QDB4NB?=
HT1080 NYLZNpBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLNN48xNjByMEGtNVAxKM7:TR?= NX\w[4NvOjRiaB?= M4C1[WROW00EoB?= NYTrfpRH[2G3c3XzJIFvKGmwY4LlZZNmKGmwIITo[UBvfW2kZYKgc4Yh[2WubIOgbY4hTzJxTTyge4hqdGViZHXjdoVie2mwZzDTJIFv\CCJMTDwbIF{\SClZXzsdy=> NVTwNVIyOjVyN{iwOlQ>
HD-MY-Z M3HjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfRNlQwPDhxN{KgbC=> MVLJR|Ux97zgMUCwJO69VQ>? MWqyOVA1QDJ|Nh?=
DOHH-2 NHjkVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVOxV2xZOjRiaB?= MX\JR|Ux97zgMUCwJO69VQ>? MV[yOVA1QDJ|Nh?=
DOHH-2 MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHJOFghcA>? M4nyS2lEPTB;MUmuPeKh|ryP M17tcFI2ODR6MkO2
DOHH-2 NIj6coJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmO1O|IhcA>? MWHJR|UxRTYEoN88US=> MlWyNlUxPDh{M{[=
REH MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK5NlQhcA>? MmPLTWM2OD1yLkCyO:Kh|ryP MV2yOVA1QDJ|Nh?=
REH MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DNVVQ5KGh? NEjUSXNKSzVyPUCuNFE1yqEQvF2= NGjhbY4zPTB2OEKzOi=>
REH MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUe3NkBp MXXJR|UxRTBwMEG1xsDPxE1? NEfOUmUzPTB2OEKzOi=>
HH MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUmyXFJCOjRiaB?= NYXoZWR{UUN3ME2xNFQvP8LizszN MYiyOVA1QDJ|Nh?=
HH MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nU[VQ5KGh? NET1S3BKSzVyPUS4MlbDqM7:TR?= Mom3NlUxPDh{M{[=
HH M2qxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe3c2s4OiCq MY\JR|UxRTF2LkhCpO69VQ>? Ml;sNlUxPDh{M{[=
HuT-78 NGHUfnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjoUXQzPCCq NUfqSoNlUUN3ME25MlPDqM7:TR?= M{LjcVI2ODR6MkO2
HuT-78 NYnpR4xMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHaOFghcA>? NUThW4h2UUN3ME20MlPDqM7:TR?= MXiyOVA1QDJ|Nh?=
HuT-78 M2G5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PVVlczKGh? M{fsbWlEPTB;ND6yxsDPxE1? MYCyOVA1QDJ|Nh?=
OPM-2 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETUOmczPCCq MlLYTWM2OD1{ND6xxsDPxE1? MonlNlUxPDh{M{[=
OPM-2 MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXGOFghcA>? M2TUd2lEPTB;NNMg{txO NH7ud2MzPTB2OEKzOi=>
OPM-2 NUjkeGtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3m3blczKGh? Ml3pTWM2OD1zLkRCpO69VQ>? NXPQUIZ3OjVyNEiyN|Y>
RPMI-8226 NVXaXWJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHPNlQhcA>? NWW5bIxQUUN3ME2xNFYvPsLizszN NX7zd2p4OjVyNEiyN|Y>
RPMI-8226 NFnJSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTDOFghcA>? MkPmTWM2OD17MT6xxsDPxE1? MViyOVA1QDJ|Nh?=
RPMI-8226 M2D0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS5W5k4OiCq MlLpTWM2OD1zND65xsDPxE1? NHr2PGIzPTB2OEKzOi=>
U-266 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD3NlQhcA>? MYLJR|UxRTh4LkNCpO69VQ>? M2nhWFI2ODR6MkO2
U-266 MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\4WHZpPDhiaB?= MonMTWM2OD14OD60xsDPxE1? MnnwNlUxPDh{M{[=
U-266 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLMV|FTPzJiaB?= NXO5R5Y1UUN3ME2yO{41yqEQvF2= NGjEeW0zPTB2OEKzOi=>
Kelly MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCwMVExKM7:TR?= MW[3NuKhcA>? MnXMTWM2OD1zLkWxPOKh|ryP M2PFTFI2ODB6OUCw
SH-SY5Y  MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLjbocxNTFyIN88US=> NIP2Tnk4OsLiaB?= NFHFdJlKSzVyPUCuO|U1yqEQvF5CpC=> M4fUfFI2ODB6OUCw
SK-N-AS NGS2fIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G1bFAuOTBizszN MXm3NuKhcA>? NEDrWGtKSzVyPUGuO|EzyqEQvF5CpC=> NGDQbW4zPTByOEmwNC=>
SK-N-DZ NVjOUZpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2wMVExKM7:TR?= MYS3NuKhcA>? M2rIVWlEPTB;NT60PFXDqM7:TR?= MmPBNlUxODh7MEC=
HepG2 NHPCWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjvcIM1QMLiaB?= NFvVblZFVVORwrC= NF\WU3dKSzVyPUGzMlY2yqEEsdMgNE46OsLizszN MVWyOFk6PjF|Nh?=
A549 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTHOFjDqGh? NXXRem1lTE2VT9Mg NX\oXZpkUUN3ME2yOFEvQcLiwsJCpFMyNjJ|wrFOwG0> MnnFNlQ6QTZzM{[=
MCF7 M2XKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXGOFjDqGh? NGrxTG1FVVORwrC= NYDyXohOUUN3ME24NU4xQcLiwsJCpFE1NjJzwrFOwG0> MWCyOFk6PjF|Nh?=
HL-60  NUDZRmptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[3NuKhcA>? MknDTWM2OD1yLkGy5qCG|ryP NX3tVpVZOjR7OUOwNVQ>
HL-60[R] M3HmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvCcXV{PzMEoHi= MV7JR|UxRTNwMUNihKXPxE1? MmS5NlQ6QTNyMUS=
MIAPACA NIHNN4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PaNWdKPTB;MT6zJOKyKDBwMEOg{txO Ml3UNlQ6PTN6MkG=
MCF-7 MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3KyO2dKPTB;MD6yOUDDuSByLkGg{txO NFH0e4kzPDl3M{iyNS=>
HeLa NXXvPWRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;HTVUxRTBwNkSgxtEhOC52IN88US=> MnTKNlQ6PTN6MkG=
MO59K  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUS3JIQ> NWL5UGRYUUN3ME2wMlE46oDHzszN NUPyV5ZoOjR7NUO1OlE>
MO59J MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7kdGU4KGR? MWjJR|UxRTBwMfMAie69VQ>? M4rwbFI1QTV|NU[x
ME 180 MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV20POKhcMLi NWfxdJo3UUN3ME24MlnDqMLzwrCwMlPjiIYQvF2= NGm3[ZczPDl3M{CyOy=>
MCF-7 NGXGUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PQRlQ5yqCqwrC= NH[zcJlKSzVyPUKzMlkhyrFiMD6z5qCG|ryP MViyOFk2OzB{Nx?=
HeLa NFO4fJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPIOFjDqGkEoB?= NYLoNZA{UUN3ME20MlcyKMLzIEGuOQKBjc7:TR?= MWGyOFk2OzB{Nx?=
MDA-MB-453 MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PLSVQ5yqCqwrC= MV7JR|UxRTF{LkWgxtEhOC56NfMAie69VQ>? Ml7jNlQ6PTNyMke=
MDA-MB-231 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVK0POKhcMLi NX[zb4JjUUN3ME2yOE4zOiEEsTCyMlk16oDHzszN NYPJN|ZtOjR7NUOwNlc>
PC-3 Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTQfXV[PDkEoHlCpC=> M{jHT2lEPTB;MUSuOEDDuSB|LkKz5qCG|ryP NITUS|MzPDl3M{CyOy=>
HT-29 M2j4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj3OFjDqGkEoB?= NVjLU3VIUUN3ME2yNU41PSEEsTCzMlg46oDHzszN MXSyOFk2OzB{Nx?=
BGC-823 NG\RXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWm0POKhcMLi M2nVbWlEPTB;NEOuO|QhyrFiNT6xN-KBjc7:TR?= MWOyOFc6Ozh5Nx?=
HeLa MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULwcG5VPDkEoHlCpC=> NHPJbnZKSzVyPUKwPU46OCEEsTCxN{41OiEkgJZOwG0> NFHYWWgzPDd7M{i3Oy=>
A549 NIPVeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfaPFI1QMLiaNMg NIGyUVNKSzVyPUGzPU42PCEEsTC3MlA26oDHzszN Ml3pNlQ4QTN6N{e=
HK-2 MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjO[lV{PDkEoHlCpC=> MXnJR|UxRTlwMUegxtEhOS53OPMAie69VQ>? MlXBNlQ4QTN6N{e=

... Click to View More Cell Line Experimental Data

体内研究 Etoposide 作用于Lewis 肺癌,诱导肿瘤免疫。Etoposide按50 mg/kg剂量单独腹腔注射给药注射了Lewis肺癌细胞 (3LL)的C57B1/6小鼠,诱导60%存活。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[5]
+ 展开

Topoisomerase II 活性测定:

制备核提取物,进行核分离。在Topoisomerase II去连环过程中获得去连环百分数而计算Topoisomerase II的活性。氚标记的kinoplast DNA (KDNA 0.22 μg)作为底物。Etoposide 与 Topoisomerase II在37°C 下温育30分钟,然后加入1%十二烷基硫酸钠(SDS)和蛋白酶K(100 μg/mL)终止。通过Etoposide获得去连环百分数和 Topoisomerase II 抑制情况。
细胞实验:[5]
+ 展开
  • Cell lines: 人类胶质瘤细胞系CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 小时
  • Method: Etoposide处理后,使用含有0.03%胰蛋白酶和0.27 mM乙二胺四乙酸(EDTA)的磷酸盐缓冲液(PBS)将细胞从培养皿中移去,然后在培养皿中稀释到适当数目,获得20到200个菌落。12天后,使用甲醇-乙酸固定培养基,使用结晶紫进行染色,并计数超过50个细胞的菌落。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 携带血管肉瘤移植瘤ISOS-1 的小鼠
  • Formulation: 生理盐水
  • Dosages: 10 mg/kg
  • Administration: 从实验第7天开始,每天腹腔注射,持续5天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+H2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 588.56
化学式

C29H32O13

CAS号 33419-42-0
稳定性 powder
in solvent
别名 VP-16, VP-16213

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT03349346 Withdrawn Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03349346 Withdrawn Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

相关Topoisomerase产品

Tags: 购买Etoposide | Etoposide供应商 | 采购Etoposide | Etoposide价格 | Etoposide生产 | 订购Etoposide | Etoposide代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID